nach oben

Inflammation Research

Erschienen in:

01.12.2013 | Original Research Paper

Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases

Erschienen in: Inflammation Research | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Serum amyloid A (SAA), secreted group IIA phospholipase A₂ (sPLA₂-IIA), and C-reactive protein (CRP) are acute-phase proteins whose serum concentrations increase not only during inflammatory disorders, but also in the course of malignant diseases.

Materials and methods

In this study we analyzed serum levels of these inflammatory markers along with prostate-specific antigens (PSA) in patients with benign prostatic hyperplasia (BPH, n = 55), localized prostate cancers (PCa, n = 55), and metastatic prostate cancers (mPCa, n = 27) using immunological assays.

Results

We found that in comparison to healthy individuals (n = 55), patients with BPH, PCa and mPCa have elevated serum levels of SAA, sPLA₂-IIA, and CRP, in addition to elevated levels of PSA. Significant differences with respect to inflammatory biomarkers were found between localized and metastatic PCa (p < 0.001), suggesting a prognostic value of these parameters. In addition, serum concentrations of SAA and sPLA₂-IIA positively correlate with CRP in BPH patients (p < 0.05) and in patients with PCa and mPCa (p < 0.001), but not with PSA levels, Gleason score, or tumor stage, emphasizing a role of SAA and sPLA₂-IIA as circulating biomarkers of inflammation rather than of neoplastic transformation. In contrast to PSA, which differed significantly between BPH and localized PCa patients (p < 0.01), such a difference was not found for SAA, sPLA₂-IIA, and CRP. In order to elucidate whether the elevated levels of SAA and sPLA₂-IIA can be caused by cancer cell-associated synthesis, in vitro studies were performed. These analyses demonstrated the expression of SAA and sPLA₂-IIA in LNCaP and PC-3 prostate cell lines, which can be further upregulated by pro-inflammatory cytokines in a cell type-dependent manner. This might suggest that, in addition to the hepatic origin, SAA and sPLA₂-IIA can also be synthesized and secreted by prostatic cancer tissue itself.

Conclusion

The results of the present study emphasize the utility of SAA, sPLA₂-IIA, and CRP as circulating biomarkers of inflammation during BPH development and PCa progression.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef

McDowell ME, Occhipinti S, Gardiner RA, Baade PD, Steginga SK. A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer. Eur J Cancer Care (Engl). 2009;18:545–55.CrossRef

Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33:475–88.PubMedCrossRef

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(Suppl 1):S2–11.PubMedCrossRef

Artibani W. Landmarks in prostate cancer diagnosis: the biomarkers. BJU Int. 2012;110(Suppl 1):8–13.PubMedCrossRef

Schröder FH. Landmarks in prostate cancer screening. BJU Int. 2012;110(Suppl 1):3–7.PubMedCrossRef

Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins - Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol. 2012;91:496–505.PubMedCrossRef

Kanoh Y, Ohtani H, Egawa S, Baba S, Akahoshi T. Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol. 2011;39:1553–8.PubMed

Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A₂ of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006;79:1–33.PubMedCrossRef

10.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–69.PubMedCrossRef

11.

De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–17.PubMedCrossRef

12.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171:571–82.PubMedCrossRef

13.

Heikkilä K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44:937–45.PubMedCrossRef

14.

Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Inter. 2005;95:961–2.CrossRef

15.

Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a metaanalysis. Cancer Causes Control. 2009;20:15–26.PubMedCrossRef

16.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008;112:2377–83.PubMedCrossRef

17.

Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef

18.

McCall P, Catlow J, McArdle PA, McMillan DC, Edwards J. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomark. 2011;10:91–9.PubMed

19.

Triggiani M, Granata F, Giannattasio G, Marone G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol. 2005;116:1000–6.PubMedCrossRef

20.

Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, de Souza P, Dong Q, Graham GG, Russell PJ. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 2010;92:601–10.PubMedCrossRef

21.

Nagy B, Szendroi A, Romics I. Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol Oncol Res. 2009;15:279–83.PubMedCrossRef

22.

Kallajoki M, Alanen KA, Nevalainen M, Nevalainen TJ. Group II phospholipase A₂ in human male reproductive organs and genital tumors. Prostate. 1998;35:263–72.PubMedCrossRef

23.

Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH. Expression of group IIa secretory phospholipase A₂ increases with prostate tumor grade. Clin Cancer Res. 2001;7:3857–61.PubMed

24.

Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate. 2006;66:971–86.PubMedCrossRef

25.

Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008;10:279–86.PubMed

26.

Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Neumeister V, Wirth MP, Siegert G. Serum levels of secreted group IIA phospholipase A₂ in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia? Inflammation. 2012;35:1113–8.PubMedCrossRef

27.

Fischer K, Theil G, Hoda R, Fornara P. Serum amyloid a: a biomarker for renal cancer. Anticancer Res. 2012;32:1801–4.PubMed

28.

Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci. 2007;20:33–40.PubMed

29.

Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003;3:1720–4.PubMedCrossRef

30.

Vlasova MA, Moshkovskii SA. Molecular interactions of acute phase serum amyloid A: possible involvement in carcinogenesis. Biochemistry (Mosc). 2006;71:1051–9.CrossRef

31.

Kaneti J, Winikoff Y, Zimlichman S, Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res. 1984;12:239–41.PubMedCrossRef

32.

Poitou C, Divoux A, Faty A, Tordjman J, Hugol D, Aissat A, Keophiphath M, Henegar C, Commans S, Clément K. Role of serum amyloid A in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J Clin Endocrinol Metab. 2009;94:1810–7.PubMedCrossRef

33.

Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006;66:1521–34.PubMedCrossRef

34.

Oleksowicz L, Liu Y, Bracken RB, Gaitonde K, Burke B, Succop P, Levin L, Dong Z, Lu S. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate. 2012;72:1140–9.PubMedCrossRef

35.

Dong Z, Liu Y, Scott KF, Levin L, Gaitonde K, Bracken RB, Burke B, Zhai QJ, Wang J, Oleksowicz L, Lu S. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis. 2010;31:1948–55.PubMedCrossRef

36.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef

37.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.PubMedCrossRef

38.

Diamandis EP. Proteomic patterns in serum for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst (Bethesda). 2004;96:353–6.CrossRef

39.

Nevalainen TJ, Kallajoki M, Pesonen E, Andersson S, Kärkkäinen P, Höckerstedt K. Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epithelioid hemangioendothelioma of the liver. Lab Invest. 1996;74:585–91.PubMed

40.

Laye JP, Gill JH. Phospholipase A₂ expression in tumors: a target for therapeutic intervention? Drug Dis Today. 2003;8:710–6.CrossRef

41.

Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M. Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer. 1993;71:3058–64.PubMedCrossRef

42.

Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N, Miwa M. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res. 2002;8:1157–67.PubMed

43.

Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68:4277–86.PubMedCrossRef

44.

Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. APMIS. 2009;117:151–61.PubMedCrossRef

45.

Kim HJ, Kim KS, Kim SH, Baek SH, Kim HY, Lee C, Kim JR. Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. J Gerontol A Biol Sci Med Sci. 2009;64:351–62.PubMedCrossRef

46.

Xing XF, Li H, Zhong XY, Zhang LH, Wang XH, Liu YQ, Jia SQ, Shi T, Niu ZJ, Peng Y, Du H, Zhang GG, Hu Y, Lu AP, Li JY, Chen S, Ji JF. Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology. 2011;59:198–206.PubMed

47.

Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR, Honn KV. Platelet-type 12-lipoxygenase activates NF-κB in prostate cancer cells. Prostaglandins Other Lipid Mediat. 2003;71:189–204.PubMedCrossRef

48.

Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006;66:1427–33.PubMedCrossRef

49.

Sadaria MR, Yu JA, Meng X, Fullerton DA, Reece TB, Weyant MJ. Secretory phospholipase A₂ mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway. Anticancer Res. 2013;33:1337–42.PubMed

50.

Hernández M, Martín R, García-Cubillas MD, Maeso-Hernández P, Nieto ML. Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol. 2010;12:1014–23.PubMedCrossRef

51.

Yu JA, Kalatardi S, Dohse J, Sadaria MR, Meng X, Fullerton DA, Weyant MJ. Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells. Anticancer Res. 2012;32:3601–7.PubMed

52.

Yu JA, Mauchley D, Li H, Meng X, Nemenoff RA, Fullerton DA, Weyant MJ. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg. 2012;144:1185–91.PubMedCrossRef

53.

Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005;330:989–98.PubMedCrossRef

Titel: Serum amyloid A, phospholipase A2-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases
Publikationsdatum: 01.12.2013
Erschienen in: Inflammation Research / Ausgabe 12/2013
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0665-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis

The effect of 7-ketocholesterol and 25-hydroxycholesterol on the integrity of the human aortic endothelial and intestinal epithelial barriers

Paeoniflorin inhibits inflammatory responses in mice with allergic contact dermatitis by regulating the balance between inflammatory and anti-inflammatory cytokines

Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure

Direct comparison of laser Doppler flowmetry and laser Doppler imaging for assessment of experimentally-induced inflammation in human skin